Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + Anlotinib Maintenance in Limited-Stage SCLC
NCT06469879Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06469879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469879.